💊 Препараты А-Я 🧬 Мишени 🛠 Инструменты 📚 Руководства
Все препараты Классы препаратов Терапевтические области Побочные Эффекты
Руководства Глоссарий Хронология
Сравнения Путешествия препаратов Группы лекарственных средств
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Sulfinpyrazone

CHEMBL832 Phase 4 Одобрено Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
404.5 g/mol
LogP
2.3
Phase
4

Sulfinpyrazone is a uricosuric agent and antiplatelet drug used for the treatment of hyperuricemia and chronic gout by inhibiting tubular reabsorption of uric acid in the kidney, increasing renal uric acid excretion and lowering serum urate levels. It also inhibits platelet cyclooxygenase and thromboxane synthesis, with antiplatelet properties that were investigated for prevention of thromboembolic events. It is used as an alternative to probenecid in patients intolerant of allopurinol.

Молекулярная масса

404,5000 g/mol

LogP

2,30

TPSA

76,90 Ų

Правило пяти Липинского

Соответствует

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Структура

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
O=C1C(CC[S+]([O-])c2ccccc2)C(=O)N(c2ccccc2)N1c1ccccc1

                

                

                
                

                    
InChI

                    
InChI=1S/C23H20N2O3S/c26-22-21(16-17-29(28)20-14-8-3-9-15-20)23(27)25(19-12-6-2-7-13-19)24(22)18-10-4-1-5-11-18/h1-15,21H,16-17H2

                

                

                

                    
                    

                        
Molecular Formula

                        
C23H20N2O3S

                    

                    
                    

                        
HBD / HBA

                        
- / 4

                    

                    
                    

                        
Вращаемые Связи

                        
6

                    

                    
                    
                    

                        
Тяжёлые Атомы

                        
29

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Часто задаваемые вопросы

                

                    
                    

                        
                        

                            
Sulfinpyrazone is a uricosuric agent and antiplatelet drug used for the treatment of hyperuricemia and chronic gout by inhibiting tubular reabsorption of uric acid in the kidney, increasing renal uric acid excretion and lowering serum urate levels. It also inhibits platelet cyclooxygenase and thromboxane synthesis, with antiplatelet properties that were investigated for prevention of thromboembolic events. It is used as an alternative to probenecid in patients intolerant of allopurinol.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Sulfinpyrazone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL832.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 5342.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Медицинский отказ от ответственности

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.